
    
      Part 1 of the study comprises:

        -  A screening period of maximum 28 days.

        -  Three treatment periods during which subjects will reside in the Clinical Unit from Day
           -2, Treatment Period 1 until at least 48 hours after dosing on Day 1, Treatment Period
           3, ie, subjects will be discharged the morning of Day 3, Treatment Period 3.

        -  A Follow-up Visit within 7 to 10 days after the last dose of acalabrutinib.

      There will be a minimum washout period of 4 days between treatment periods. Up to 20 subjects
      will be included to ensure at least 16 subjects are evaluable. Subjects will be randomized to
      one of 2 treatment sequences (ABC, BAC) and each subject will receive single doses of 3
      treatments under fasted conditions.

      Part 2 of the study comprises:

        -  A screening period of maximum 28 days.

        -  Two treatment periods during which subjects will reside in the Clinical Unit from Day
           -2, Treatment Period 1 until at least 48 hours after dosing on Day 1, Treatment Period
           2, ie, subjects will be discharged the morning of Day 3, Treatment Period 2.

        -  A Follow-up Visit within 7 to 10 days after the last dose of acalabrutinib.

      There will be a minimum washout period of 4 days between treatment periods. Up to 20 subjects
      will be included to ensure at least 16 subjects are evaluable. Subjects will be randomized to
      one of 2 treatment sequences (DA, AD) and each subject will receive single doses of 2
      treatments under fasted conditions.
    
  